Are Jenburkt Pharma latest results good or bad?
Jenburkt Pharmaceuticals reported a flat financial performance for the quarter ending March 2025, with net sales growth of 11.28% and net profit growth of 31.18%, indicating some operational improvements. However, concerns about the sustainability of rising non-operating income and recent adjustments in the company's evaluation suggest ongoing challenges.
Jenburkt Pharmaceuticals has reported its financial results for the quarter ending March 2025, revealing a flat financial performance compared to previous quarters. The company experienced a net sales growth of 11.28% and a standalone net profit growth of 31.18% in this quarter, contrasting with declines in the previous quarter. This indicates some operational improvements in sales and profitability metrics.However, it is important to note that while non-operating income has risen to Rs 1.88 crore, marking the highest level in the last five quarters, there are concerns regarding the sustainability of this income from non-business activities. The overall performance suggests that the company is facing challenges that may need to be addressed to enhance its financial standing.
Additionally, there has been an adjustment in the company's evaluation over the last three months, indicating a change in perception regarding its financial health. Stakeholders will likely be monitoring future developments closely as Jenburkt Pharmaceuticals navigates these results.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
